NCT00386633View on ClinicalTrials.gov

Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

November 30, 2007

Conditions

HIV Infections

Interventions

BIOLOGICAL

MVA-mBN32

3 immunizations; first study group: 10E7\_TCID50

BIOLOGICAL

MVA-mBN32

3 immunizations; second study group: 10E8\_TCID50

Trial Locations (1)

80799

LMU-Munich, Department of Infectious Diseases and Tropical Medicine, Munich

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY